Data on VIVUS' Qnexa To Be Featured at The Obesity Society Annual Meeting

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq:
VVUS) today announced that data on Qnexa(TM), an investigational new drug,
will be presented at the 27th annual scientific meeting of The Obesity Society
(TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical
development at VIVUS, will present data from the company's two year long phase
3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair
of the department of nutrition sciences at the University of Alabama at
Birmingham, will present data from the year long phase 2 study in type 2
diabetics.

"I am pleased that Dr. Day and Dr. Garvey can share the results of the phase 3
obesity studies and phase 2 obesity studies with our colleagues in the medical
and pharmaceutical community," stated Leland Wilson, president and chief
executive officer of VIVUS. "We are actively pursuing a comprehensive
presentation and publication strategy, and are excited by the opportunity to
communicate these data at Obesity Society's annual meeting. We look forward to
additional presentations in the future with the ultimate goal of publication
in a top-tier medical journal."

Following are details about the upcoming presentations:

27th Annual Scientific Meeting of The Obesity Society, October 24-28, 2009,
Marriott Wardman Park Hotel, in Washington, DC

Date and Time: Saturday, October 24, 2009, 1:00 PM EDT
Session: Preconference
Presentation: Pharmacotherapy Update
Chairs: Ken Fujioka, MD, Louis J. Aronne, MD, and Richard Pratley, MD
Presenter: Wesley W. Day, PhD

Date and Time: Sunday, October 25, 2009, 5:30 PM EDT
Session: Pharmacotherapy
Presentation Title: "One-Year Treatment with Low Dose VI-0521 in Type 2
Diabetes Demonstrates Sustained Weight Loss and Continuous Glycemic Benefit"
Presenter: W. Timothy Garvey, MD

About Qnexa

Qnexa (Q-NEX-uh) is a once-a-day, proprietary, oral, controlled-release
formulation of low dose phentermine and topiramate, which is believed to
address both appetite and satiety - the two main mechanisms that impact eating
behavior - in one capsule. Qnexa, an investigational drug, is being developed
to address weight loss. In phase 2 and 3 clinical data to date, Qnexa has
demonstrated significant weight loss, glycemic control, and improvement in
cardiovascular risk factors.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation
therapies to address unmet needs in obesity, diabetes and sexual health. The
company's lead product in clinical development, Qnexa(TM), has recently
completed phase 3 clinical trials for the treatment of obesity. Qnexa is also
in phase 2 clinical development for the treatment of type 2 diabetes. In the
area of sexual health, VIVUS is in phase 3 development with avanafil, a
potentially best-in-class PDE5 inhibitor, and in phase 2 development of
Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in
women. MUSE® (alprostadil), a first generation therapy for the treatment of
ED, is already on the market and generating revenue for VIVUS. For more
information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on VIVUS' current expectations and
actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; reliance on
sole source suppliers; limited sales and marketing efforts and dependence upon
third parties; risks related to the development of innovative products; and
risks related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. As with any pharmaceutical under
development, there are significant risks in the development, regulatory
approval and commercialization of new products. There are no guarantees that
future clinical studies discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. VIVUS does not undertake an
obligation to update or revise any forward-looking statement. Investors should
read the risk factors set forth in VIVUS' Form 10-K for the year ended
December 31, 2008 and periodic reports filed with the Securities and Exchange
Commission.

CONTACT:

VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
650-934-5200

Investor Relations:
The Trout Group
Brian Korb
646-378-2923

Media Relations:
Pure Communications, Inc.
Sheryl Seapy
949-608-0841

SOURCE VIVUS, Inc.

VIVUS, Inc., Timothy E. Morris, Chief Financial Officer, +1-650-934-5200;
Investor Relations: The Trout Group, Brian Korb, +1-646-378-2923; or Media
Relations: Pure Communications, Inc., Sheryl Seapy, +1-949-608-0841